News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Antibody Drug Conjugate Market Outlook 2018”, significant advancements in linking technologies have fuelled interest in ADCs. These advancements have paved the development of drugs such as ADCETRIS and Kadcyla. The industry is developing more precise and optimal positioning of the link between the cytotoxin and the antibody, resulting in a “homogeneous” product that may assure more efficient delivery of cytotoxin to the tumor cell, resulting in better efficacy and less toxicity.
 
Recently Scientists at the Scripps Research Institute have developed improved linkages in the form of Thiol-Click reaction. They have described a way to make improved linkages using compounds based on methylsulfonyl-substituted heterocycles instead of maleimides. The method resulted a more stable and specific linkage between antibody and cytotoxic agent. Similar efforts to develop linkers based on multiple isomers have been made by the PolyTherics and Meditope Biosciences. This technology may provide the way for better positioning and release of ADC payload to the site.
 
This report is spread over 60 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.
 
The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.
 
At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm